Sector News

AZ ups stake in Moderna

August 11, 2016
Life sciences

AstraZeneca has bumped up its stake in US biotech Moderna, which is pioneering the development of a new class of drugs made of messenger RNA, to nine percent.

The UK-listed group said it is investing a further $140 million to increase its equity interest in the company, adding to its previous stake garnered through a collaboration agreement signed back in March 2013.

The parties initially hooked up to develop medicines for cardiovascular, metabolic and renal diseases, as well as oncology, and subsequently signed another agreement in January this year solely focused on the development of cancer therapies.

The companies coupling AstraZeneca group MedImmune’s protein engineering and cancer biology expertise with Moderna’s technology platform in the hope of developing new mRNA-based therapies.

These enable the body to produce therapeutic protein in vivo, and thus potentially offer a new treatment approach for a wide range of diseases.

By Selina McKee

Source: Pharma Times

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach